Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients

Blood

Volumn 112, Issue 4, 2008, Pages 1085-1090

  Santilli, Francesca ^a   Romano, Mario ^a   Recchiuti, Antonio ^a   Dragani, Alfredo ^b   Falco, Angela ^a   Lessiani, Gianfranco ^a   Fioritoni, Francesca ^b   Lattanzio, Stefano ^a   Mattoscio, Domenico ^a   De Cristofaro, Raimondo ^c   Rocca, Bianca ^a   Davì, Giovanni ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Pescara Hospital   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; THROMBOXANE A2; VON WILLEBRAND FACTOR; ARGININE; DIMETHYLARGININE; DRUG DERIVATIVE; THROMBOXANE; THROMBOXANE B2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLONY FORMING CELL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HUMAN; IN VIVO STUDY; LOW DRUG DOSE; MALE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; STEM CELL; THROMBOSIS; TREATMENT RESPONSE; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; CLONOGENIC ASSAY; DRUG EFFECT; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ARGININE; ASPIRIN; BLOOD; CASE-CONTROL STUDIES; COLONY-FORMING UNITS ASSAY; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; STEM CELLS; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANES;

EID: 51649130509     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-123091     Document Type: Article

References (36)

1. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995;123: 656-664.
2. Landolfi R, Ciabattoni G, Patrignani P. et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin- suppressible platelet activation in vivo. Blood. 1992:80:1965-1971.
3. Patrono C, García Rodriguez LA. Landolfi R. Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373-2383.
4. Michiels JJ, Berneman Z. Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets. 2006; 17:528-544.
5. Landolfi R; Marchioli R, Kutti J, et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
6. NeunteufI T, Heher S, Stefenelli T, Pabinger I, Gisslinger H. Endothelial dysfunction in patients with polycythaemia vera. Br J Haematol. 2001; 115:354-359.
7. Asahara T. Murohara T. Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
8. Young PP, Vaughan DE, Hatzopoulos AK. Biologic properties of endothelial progenitor cells anc their potential for cell therapy. Prog Cardiovasc Dis. 2007;49:421-429.
9. Hill JM, Zalos G, Halcox JR et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593-600.
10. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007.
11. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol. 2005;46:1693-1701.
12. Boger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med. 2005;10:S19-S25.
13. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117:1449-1459.
14. Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on PVSG protocols. Semin Hematol. 1986; 23:132-143.
15. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of Essential Thrombocythemia and Polycythemia Vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost. 1997; 23:339-347.
16. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109:1801-1809.
17. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med. 2004;42:1377-1383.
18. 2 production in healthy subjects. Thromb Res. 1980;17:317-327.
19. 2 in human plasma and urine. Biochim Biophys Acta. 1987;918:293-297.
20. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372.
21. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclo-oxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 2002; 99:7634-7639.
22. Davì G, Patrono C. Platelet activation in athero-thrombosis. N Engl J Med. 2007;357:2482-2494.
23. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
24. Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP). Br J Haematol. 1997:97:453-456.
25. FitzGerald GA, Oates JA; Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676-688.
26. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program. 2006;240-245.
27. Datta YH. Romano M, Jacobson BC, Golan DE. Serhan CN; Ewenstein BM. Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation. 1995;92:3304-3311.
28. Schnabel R, Blankenberg S. Oxidative stress in cardiovascular disease. Successful translation from bench to bedside? Circulation. 2007;116:1338-1340.
29. Aicher A, Heeschen C, Mildner-Rihm C, et al. essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003:9;1370-1376.
30. Kanaganayagam G. Marber MS. ADMAring endothelial progenitor cells accident, association, or antecedent. J Am Coll Cardiol. 2005;46:1702-1704.
31. Matsumoto Y Ueda S, Yamagishi S, et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol. 2007;18:1525-1533.
32. Cooper MR, DeChatelet LR, McCall CE, Spurr CL. The activated phagocyte of polycythemia vera. Blood. 1972;40:366-374.
33. Hattangadi SM, Lodish HE Regulation of erythrocyte lifespan: do reactive oxygen species set the clock? J Clin Invest. 2007;117:2075-2077.
34. Patrono C, Falco A, Davl G. Isoprostane formation and inhibition in atherothrombosis. Gurr Opin Pharmacol. 2005;5:198-203.
35. Eikelboom JW, Hirsh J, Weitz Jl, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002; 105:1650-1655.
36. Spivak J. Daily aspirin: only half the answer. N Engl J Med. 2004;350:99-102.